Literature summary for 3.4.21.98 extracted from

Yang, C.M.; Yoon, J.C.; Park, J.H.; Lee, J.M.
Hepatitis C virus impairs natural killer cell activity via viral serine protease NS3 (2017), PLoS ONE, 12, e0175793 .

Search for more literature for 3.4.21.98

Application

Application	Comment	Organism
drug development	NS3 protease represents a drug target for treatment of HCV infections	Hepatitis C virus genotype 2a

Inhibitors

Inhibitors	Comment	Organism	Structure
BILN-2061	a NS3 serine protease inhibitor	Hepatitis C virus genotype 2a

Organism

Organism	UniProt	Comment	Textmining
Hepatitis C virus genotype 2a	Q99IB8	HCV, isolate JFH-1	-

Source Tissue

Source Tissue	Comment	Organism	Textmining

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
additional information	NS3 acts as a serine protease and helicase	Hepatitis C virus genotype 2a	?	-	?

Synonyms

Synonyms	Comment	Organism
NS3	-	Hepatitis C virus genotype 2a
NS3 serine protease	-	Hepatitis C virus genotype 2a

General Information

General Information	Comment	Organism
malfunction	treatment of virus-infected cells with NS3 enzyme inhibitor BILN-2061 significantly increases degranulation against K-562 target cells and IFN-gamma productivity in natural killer (NK) cells of the host. The expression levels of activating NK cell receptors, such as NKp46 and NKp30, are also increased	Hepatitis C virus genotype 2a
physiological function	hepatitis C virus impairs natural killer cell activity via viral serine protease NS3. The modulation of natural killer (NK) cell functions by HCV leads to an impaired innate immune response. In HCV-infected Huh-7.5 cells, the serine protease NS3 may play a role in the abrogation of NK cell functions in the early phase of infection through downregulation of NKp46 and NKp30 receptors on NK cells. HCV-NS replicon and HCV-NS3-transfected Huh-7.5 cells attenuate NK cell functions, overview	Hepatitis C virus genotype 2a

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)